On November 2, 2021, Biolinq Inc closed the transaction. The company raised $100,000,000 in the transaction. The round is led by RiverVest Venture Partners, LLC.

The transaction included participation from T&W Medical, Ascensia Diabetes Care Holdings AG, Longevity Vision Fund, a fund managed by Longevity Vision Investment Advisors, LLC, Falcon Edge Capital, LP, Aphelion Capital, LLC, Senvest Capital Inc, The Broe Group, Taisho Pharmaceutical Holdings Co., Ltd., Cirrus Logic, Inc, EOFLOW Co.,Ltd, _Able Partners NYC, LLC, new investors AXA IM Alts, Global Health Investment Fund I, LLC, a fund managed by Global Health Investment Advisors, LLC, returning investors Merck Ventures B.V., Hikma Ventures Limited and JDRF T1D Fund, a fund managed by returning investor Juvenile Diabetes Research Foundation International Inc., Endowment Arm. The company has raised $37,821,569 in its final tranche. The company has raised $77,946,902 pursuant to exemption provided under Regulation D from 62 investors.